Nucleic Acid Therapeutics (NATs): Advances and Perspectives

Dear Colleagues,

The field of nucleic acid therapeutics (NATs) has attracted a tremendous amount of interest in the past few decades. The increasing number of approved nucleic acid drugs demonstrates the potential of these therapies to treat a variety of diseases from neuromuscular disorders to cancers. Nucleic acid therapeutics act via multiple mechanisms of action, including gene silencing, activation, modulation, replacement, or editing. Continuous advances in the chemistry and design of these cutting-edge genetic drugs have led to numerous successful clinical applications, eliciting even more interest from researchers, including both academic groups and drug development companies. Clinical translation largely depends on delivery technologies that facilitate internalization and improve stability and target affinity.

The aim of this Special Issue is to cover recent advances in the field of nucleic acid therapeutics, including antisense oligonucleotides, small interfering RNA conjugates, lipid nanoparticles, and RNA and gene-editing technologies. We would like to put emphasis on their broad therapeutic potential due to the variety of mechanisms of action and the different tissues and diseases they can target. We invite contributions in the form of original research articles and reviews.

We look forward to your contributions.

Dr. Aurélie Goyenvalle
Dr. Simon Guiraud
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.